15 news items
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL
6 May 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
OCUL
6 May 24
of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
OCUL
3 May 24
"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
OCUL
1 May 24
"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
OCUL
18 Apr 24
vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD
vl1od si22qen04nrjbaepfdjkdg0dcauj6s7rxnflq
OCUL
16 Apr 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
ukw54tytpamw9u9jj3jc3038hgc8gm4t
OCUL
15 Apr 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet
2060an7tya8cyfl3c04mw71hm 4n
OCUL
9 Apr 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
fy62i1df4z2o 7phrc7i8xbol27mffpvr0xybx1ela73emgxxx0eex4q2wzb
OCUL
6 Apr 24
"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
cxw0g465jzyy1 ob9nwo2fc2a5dt0
OCUL
26 Mar 24
of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced
wjr a28u7h9akh19sdss16v2m5waqc3g4dhvq4pf2hakrophte
OCUL
5 Mar 24
of innovative therapies for retinal disease and other diseases and conditions of the eye, today announced plans to report the Company's fourth quarter and full
xcb6qikj4dgjnt2fzo8eqm0xbht3745ecnzkqwyi9year3ymes pr8jij
OCUL
22 Feb 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
h6g3g808napi qayldq7u15wu
OCUL
22 Feb 24
"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative
vmu2cbu6jxmz1rzevux2p84y2lc9b2tvv2a4ydw9rrcv725047lwtl2
OCUL
22 Feb 24
company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for diseases
4nta96woqoo7d9e27os4in6kr4 fw3wuum9a3d4jx
OCUL
19 Feb 24
, Chief Executive Officer of AffaMed. "DEXTENZA is the lead candidate in AffaMed's innovative and differentiated ophthalmology pipeline
- Prev
- 1
- Next